Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs PAGSEG Inc (PAGS) Price & Performance

IDEXX Laboratories, Inc.Trade
PAGSEG IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs PAGSEG Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while PAGSEG Inc trades at $11.14 (market cap $2.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and PAGSEG Inc for 26 Days on average.

IDXXPAGS
Market Cap
$40.43B$2.94B
Volume
692,1644,242,708
Sector
HealthIndustrials
52-Week High
$766.68$12.00
52-Week Low
$504.70$8.44
Typical Hold Time
46 Days26 Days
Enterprise Value
$41.32B$11.02B
Dividend Yield
—10.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.

Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.

PAGSEG Inc

PAGS trades at $11.16, up 6.18% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.1 and net income margin of 10.45%. Recent Q2 2026 earnings beat expectations at $0.41 per share. The company maintains a dividend yield with a $0.28 payment scheduled for September 2026. Revenue growth remains stable at $20.6B for 2026 with improving profitability.

PAGS presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. Key risks include competitive pressures in digital banking and macroeconomic sensitivity in Brazil. Analyst consensus is strongly bullish with 15 buy ratings and a $10.70 price target, though the current price exceeds this target, suggesting potential near-term consolidation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

PAGS
0% Buy100% Sell
Avg holding period · 26 Days

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About PAGSEG Inc

PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.

Read more on PAGS →